ClinConnect ClinConnect Logo
Search / Trial NCT05545306

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Sep 16, 2022

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Weight Gain Energy Expenditure Low Protein Overfeeding Fasting Natural History

ClinConnect Summary

This clinical trial is studying how different diets affect the body's energy use, particularly focusing on a process called diet-induced thermogenesis (DIT). DIT is the energy your body burns when you eat and digest food. The researchers want to see how varying the amounts of protein, fat, and carbohydrates, as well as total calories, can change this energy expenditure.

To participate in the study, you need to be a healthy adult between 18 and 60 years old who hasn’t tried to lose weight in the last six months. If you join, you’ll spend about 35 days in a clinic, eating specific foods provided by the researchers. You will follow eight different diets during your stay and undergo various tests, including measuring your body fat and conducting daily weight checks. They will also monitor your health through blood tests and other assessments. It’s important to know that certain medical conditions, like diabetes or heart disease, may prevent you from participating. Overall, this study aims to better understand how our diets impact energy use in the body.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Male or female, aged 18-60 years old
  • No episodes of intentional weight loss over previous 6 months
  • EXCLUSION CRITERIA:
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Current use of tobacco products that exceed "Very Low Dependence" on the Fagerstrom Test for Nicotine Dependence Tool (score greater than 2)
  • Diabetes
  • i. Fasting glucose \>= 126 mg/dl or hba1c \>= 6.5% or
  • ii. history of type 1 or type 2 diabetes
  • -Endocrine disorders, such as
  • i. History of Cushing s disease, pituitary disorders, or hypo- and hyperthyroidism
  • ii. TSH \<0.1 or \>= 10 uIU/mL
  • Pulmonary disorders
  • i. History of chronic obstructive pulmonary disease or other lung disease that which would limit ability to follow the protocol (investigator judgment)
  • Cardiovascular diseases,
  • i. Including history of coronary heart disease, heart failure, arrhythmias, and peripheral artery disease
  • Hypertension,
  • i. History of diagnosis and current treatment by an outside clinician
  • ii. or sitting blood pressure measurement, using an appropriate cuff, higher than
  • 140/90 mmHg
  • -Liver disease,
  • i. including history of cirrhosis, active hepatitis B or C
  • ii. AST or ALT \>=3 times upper limit of normal on screening labs
  • Renal disease
  • i. Serum creatinine \>= 1.5 mg/dls
  • Abnormal kidney function (eGFR \<60 mL/min/1.73m\^2)
  • * Central nervous system disease:
  • i. including history of previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders
  • * Cancer:
  • i. History requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer).
  • * Infectious disease:
  • i. History of active tuberculosis, HIV chronic coccidiomycosis or other chronic infections
  • Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators
  • Evidence of alcohol abuse as defined by \> =8-point score on the Alcohol consumption screening AUDIT questionnaire in adults
  • Current use of illegal drugs such as amphetamines, cocaine, opiates, or heroin; use of marijuana is permitted.
  • * For Females:
  • i. Pregnancy or lactation by history and urine pregnancy test
  • ii. Peri- or post-menopause by self-report or irregular menstrual cycle.
  • Measured weight: greater than or equal to 450 lb. (maximum weight allowed on the DXA scanning tables by the manufacturer).
  • Inability to speak or read English by self-report.
  • Inability to provide informed consent
  • History of psychological conditions including (but not limited to) claustrophobia, clinical depression, bipolar disorders, or forms of mental incapacity that would be incompatible with safe and successful participation in this study
  • Current use of medications/dietary supplements/alternative therapies known to alter energy metabolism
  • Inability to consume provided diets due to dietary concerns that will not allow them to consume \>=95% of provided calories.

About National Institute Of Diabetes And Digestive And Kidney Diseases (Niddk)

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a prominent research institution within the National Institutes of Health (NIH) dedicated to advancing scientific knowledge and promoting health in the areas of diabetes, endocrine and metabolic disorders, obesity, digestive diseases, and kidney diseases. Through rigorous clinical trials and innovative research initiatives, NIDDK aims to improve prevention, diagnosis, and treatment strategies, ultimately enhancing patient outcomes and quality of life. The institute fosters collaboration among researchers, healthcare professionals, and community stakeholders to drive impactful discoveries and translate findings into effective healthcare solutions.

Locations

Phoenix, Arizona, United States

Patients applied

0 patients applied

Trial Officials

Tomas Cabeza De Baca, Ph.D.

Principal Investigator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials